WebSep 18, 2024 · Tafasitamab is also being clinically investigated as a therapeutic option in various other B-cell malignancies, including follicular lymphoma and other indolent non-Hodgkin's lymphoma. This article summarizes the milestones in the development of … WebMar 25, 2024 · The introduction of novel targeted agents and immunotherapeutic modalities into the treatment of B-cell lymphomas has drastically shifted the treatment landscape. In diffuse large B-cell lymphoma, recent approvals of CAR T-cell therapy, the antibody-drug conjugate polatuzumab, and the anti-CD19 monoclonal antibody tafasitamab have …
Diffuse Large B-Cell Lymphoma: Relapsed/Refractory
WebImmunotherapy for lymphoma provides multiple treatment options for both adults and children, including checkpoint inhibitors and adoptive cell therapy. Lymphoma is a type of cancer that arises in the infection-fighting cells of the immune system called lymphocytes (a type of white blood cell made in the bone marrow). WebDec 17, 2024 · A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to Rituximab Versus Lenalidomide in Addition to Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma Grade 1 to 3a or R/R Marginal Zone … greater than or equal to powerapps
Phase 2 Data for Tisagenlecleucel, Tafasitamab Show Objective
WebMay 28, 2024 · TPS7568 Background: Most patients with the indolent non-Hodgkin lymphoma (NHL) subtypes FL or MZL respond to first-line treatment but relapse is common, and there is no single standard treatment for patients with R/R FL or MZL. Tafasitamab is … WebApr 1, 2024 · DLBCL coexistent with either follicular lymphoma (FL) of any grade, gastric MALT lymphoma or non-gastric MALT lymphoma; FL grade 3b; Availability of archival or freshly collected tumor tissue sent for retrospective central pathology review; IPI status of 3 to 5 (for patients > 60 years of age) or aaIPI 2 to 3 (for patients ≤ 60 years of age) WebJun 5, 2024 · Tafasitamab in combination with lenalidomide was well tolerated and resulted in a high proportion of patients with relapsed or refractory diffuse large B-cell lymphoma ineligible for autologous stem-cell transplantation having a complete ... follicular and transformed lymphoma: a phase II clinical trial. Leukemia. 2013; 27: 1902-1909. Crossref ... greater than or equal to pandas